Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SGMT Sagimet Biosciences Inc.

Pre-Mkt 09-10 04:53:03 EDT

10.86

+0.15

+1.40%

High11.27	Low10.69	Vol1.25M
Open11.25	D1 Closing10.71	Amplitude5.46%
Mkt Cap675.04M	Tradable Cap605.78M	Total Shares62.16M
T/O13.57M	T/O Rate2.24%	Tradable Shares55.78M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SGMT","market":"US","secType":"STK","nameCN":"Sagimet Biosciences Inc.","latestPrice":10.86,"timestamp":1788984000000,"preClose":10.71,"halted":0,"volume":1250131,"delay":0,"changeRate":0.014005602240896226,"floatShares":55780800,"shares":62158653,"eps":-1.248952,"marketStatus":"Pre-Mkt","change":0.15,"latestTime":"09-10 04:53:03 EDT","open":11.25,"high":11.27,"low":10.685,"amount":13567082.931299001,"amplitude":0.054622,"askPrice":11.87,"askSize":100,"bidPrice":10.67,"bidSize":3,"shortable":3,"etf":0,"ttmEps":-1.248952,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789047000000},"marketStatusCode":1,"adr":0,"listingDate":1689307200000,"exchange":"NASDAQ","adjPreClose":10.86,"postHourTrading":{"tag":"盘后","latestPrice":10.94,"preClose":10.86,"latestTime":"19:35 EDT","volume":15041,"amount":163443.7968,"timestamp":1788996933657,"change":0.08,"changeRate":0.007366,"amplitude":0.009982},"volumeRatio":1.0868868928262467,"impliedVol":1.641,"impliedVolPercentile":0.92},"requestUrl":"/m/hq/s/SGMT/","defaultTab":"news","newsList":[{"id":"2666058097","title":"Barclays Upgrades Sagimet Biosciences to Overweight From Equalweight, Adjusts Price Target to $18 From $8","url":"https://stock-news.laohu8.com/highlight/detail?id=2666058097","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666058097?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:41","pubTimestamp":1788954113,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences (SGMT) has an average rating of buy and mean price target of $29.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666408587","title":"Sagimet Biosciences Initiated at Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2666408587","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666408587?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:16","pubTimestamp":1788952560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SGMT/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666584174","title":"Sagimet Biosciences initiated with an Overweight at Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2666584174","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666584174?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:15","pubTimestamp":1788948914,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald initiated coverage of Sagimet Biosciences (SGMT) with an Overweight rating. Published first on TheFly – the ultimate source for r...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-initiated-with-an-overweight-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-initiated-with-an-overweight-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666843105","title":"Sagimet Biosciences Inc. : Barclays Raises to Overweight from Equal-Weight; Raises Target Price to $18 from $8","url":"https://stock-news.laohu8.com/highlight/detail?id=2666843105","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666843105?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:04","pubTimestamp":1788948266,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nFWN4510N6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666300172","title":"U.S. Research Roundup-Argan, Mastec, Oracle","url":"https://stock-news.laohu8.com/highlight/detail?id=2666300172","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666300172?lang=en_us&edition=fundamental","pubTime":"2026-09-09 14:55","pubTimestamp":1788936930,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Argan, Mastec, OracleSept 9 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Argan, Mastec and Oracle","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nL4N4510GB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADBG","APD","FLNC","CAI","AIRR","ANF","CRK","SMOG","AKTS","TXG","BETR","COLL","A","RTH","FSLR","TINY","ARMK","CVS","ASO","DYN","AGX","AEO","ARKG","BLTE","CLH","CC","BRZE","EVMN","ADBU","AMRZ","EXP","CTEC","BBWI","STYL","CHYM","CASY","ANIP","AMRX","FRNW","DKS","FIGR","AVTR","CRI","BRKR","ABM","IBAT","ADBE","DECK","BBOT","PLCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664815971","title":"Sagimet Biosciences to Present at Cantor Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664815971","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664815971?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:01","pubTimestamp":1788346907,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences to present at Cantor Global Healthcare ConferenceSagimet management scheduled to attend the Cantor 2026 Global Healthcare Conference in New York on Sept. 9, 2026.Fireside chat set ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL5DfZm3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3C00.GBP","SG9999014021.USD","SGMT","IE00B64PRP62.GBP","SG9999014039.USD","LU2095319765.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","LU0314104364.USD","NDAQ","IE00BKPKM429.USD","SG9999014005.SGD","BK4585","SG9999014013.SGD","IE00BN0W2T93.GBP","BK4588","BK4112","IE00BQXX3F31.USD","BK4139","LU2210150020.SGD","BCDF","IE00BQXX3D17.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664150518","title":"Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664150518","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664150518?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:00","pubTimestamp":1788346800,"startTime":"0","endTime":"0","summary":"FOSTER CITY, Calif., Sept.  02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metab","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/02/3354978/0/en/sagimet-biosciences-announces-participation-in-two-upcoming-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662755464","title":"Sagimet Biosciences Price Target Maintained with a $29.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2662755464","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662755464?lang=en_us&edition=fundamental","pubTime":"2026-08-25 23:40","pubTimestamp":1787672400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SGMT/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662753708","title":"Sagimet Reiterated as Buy on De-Risked Acne Program and Clearer Regulatory Path; $29 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2662753708","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662753708?lang=en_us&edition=fundamental","pubTime":"2026-08-25 22:45","pubTimestamp":1787669128,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences, Inc. Class A, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Brandon Folkes from H.C. Wa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/sagimet-reiterated-as-buy-on-de-risked-acne-program-and-clearer-regulatory-path-29-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/sagimet-reiterated-as-buy-on-de-risked-acne-program-and-clearer-regulatory-path-29-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LABU","BK4581","SGMT","BK4139","XLV","XBI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662773162","title":"Sagimet Biosciences advances AURORA clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2662773162","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662773162?lang=en_us&edition=fundamental","pubTime":"2026-08-25 19:40","pubTimestamp":1787658027,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences (SGMT) announced that its AURORA Phase 3 clinical trial of FASN inhibitor denifanstat in moderate to severe acne is on track to...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-advances-aurora-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-advances-aurora-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MEDX","IDNA","GDOC","SGMT","NVIB","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662036736","title":"Sagimet Advances Aurora Phase 3 Acne Trial of Denifanstat, Targets Q4 2026 Enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=2662036736","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662036736?lang=en_us&edition=fundamental","pubTime":"2026-08-25 19:02","pubTimestamp":1787655767,"startTime":"0","endTime":"0","summary":"Sagimet advances AURORA Phase 3 acne trial of denifanstat, targets Q4 2026 enrollmentSagimet advanced its AURORA U.S. Phase 3 trial of oral acne drug denifanstat toward first patient enrollment in Q4 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nNDL5M9tVX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","SG9999014021.USD","LU2210149790.SGD","NDAQ","IE00BGHQF748.EUR","IE00BQXX3D17.EUR","BCDF","IE00BKPKM429.USD","IE00BQXX3F31.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","IE00BQXX3C00.GBP","SG9999014039.USD","BK4112","IE00B64PRP62.GBP","LU2095319765.USD","IE00BN0W2W23.USD","BK4585","IE00BN0W2T93.GBP","SGMT","BK4588","BK4139","LU0314104364.USD","SG9999014013.SGD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662736194","title":"Sagimet Biosciences Advances Aurora U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662736194","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662736194?lang=en_us&edition=fundamental","pubTime":"2026-08-25 19:00","pubTimestamp":1787655600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUA7YS3FN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662573612","title":"Sagimet Biosciences - Patient Screening for Aurora Phase 3 Trial to Begin in October 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662573612","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662573612?lang=en_us&edition=fundamental","pubTime":"2026-08-25 19:00","pubTimestamp":1787655600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUA7YS3FN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662442736","title":"Sagimet Biosciences Inc.: Anticipate Submitting an Nda upon Completion of 12-Week Phase of Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2662442736","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662442736?lang=en_us&edition=fundamental","pubTime":"2026-08-25 19:00","pubTimestamp":1787655600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUA7YS3FN:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662361797","title":"Sagimet Biosciences - All Clinical Trial Sites Identified and Cro Retained for Aurora Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2662361797","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662361797?lang=en_us&edition=fundamental","pubTime":"2026-08-25 19:00","pubTimestamp":1787655600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUA7YS3FN:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660432556","title":"Sagimet Biosciences Grants 260,700 Inducement Stock Options to New Hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2660432556","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660432556?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:28","pubTimestamp":1786998504,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences grants 260,700 inducement stock options to new hiresSagimet Biosciences set inducement equity awards tied to three new hires, totaling 260,700 stock options for Series A common sha","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL7TtRXQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4588","SG9999014039.USD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4139","BCDF","LU2210149790.SGD","BK4585","IE00BN0W2T93.GBP","LU2095319765.USD","SGMT","IE00BN0W2W23.USD","LU0314104364.USD","BK4112","IE00B64PRP62.GBP","NDAQ","IE00BN0W2V16.EUR","LU2210150020.SGD","SG9999014013.SGD","SG9999014021.USD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660043253","title":"Sagimet Biosciences Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660043253","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660043253?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:28","pubTimestamp":1786998494,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nTUAB5GKRG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660508432","title":"Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660508432","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660508432?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:28","pubTimestamp":1786998480,"startTime":"0","endTime":"0","summary":"FOSTER CITY, Calif., Aug.  17, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc.(Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabol","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/17/3346482/0/en/sagimet-biosciences-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SGMT","LCLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660048943","title":"Sagimet Biosciences price target raised to $56 from $49 at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2660048943","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660048943?lang=en_us&edition=fundamental","pubTime":"2026-08-17 18:01","pubTimestamp":1786960911,"startTime":"0","endTime":"0","summary":"Canaccord raised the firm’s price target on Sagimet Biosciences (SGMT) to $56 from $49 and keeps a Buy rating on the shares. The firm said Sagimet ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-price-target-raised-to-56-from-49-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-price-target-raised-to-56-from-49-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659156990","title":"Sagimet Wins FDA IND Clearance for Phase 3 Denifanstat Acne Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2659156990","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659156990?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:05","pubTimestamp":1786619153,"startTime":"0","endTime":"0","summary":"Sagimet wins FDA IND clearance for Phase 3 denifanstat acne trialSagimet won FDA IND clearance for a Phase 3 U.S. trial of denifanstat in moderate-to-severe acne.FDA issued a “Study May Proceed” lette","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL183G6l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SGMT","IE00BN0W2W23.USD","NDAQ","LU2095319765.USD","BCDF","BK4112","SG9999014039.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BGHQF748.EUR","BK4139","LU2210150020.SGD","IE00BN0W2V16.EUR","SG9999014021.USD","SG9999014013.SGD","BK4585","IE00BKPKM429.USD","LU0314104364.USD","BK4588","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sagimet.com","stockEarnings":[{"period":"1week","weight":-0.0118},{"period":"1month","weight":0.1348},{"period":"3month","weight":0.689},{"period":"6month","weight":1.0845},{"period":"1year","weight":0.5762},{"period":"ytd","weight":0.8345}],"compareEarnings":[{"period":"1week","weight":-0.0036},{"period":"1month","weight":-0.0138},{"period":"3month","weight":0.0334},{"period":"6month","weight":0.1512},{"period":"1year","weight":0.1723},{"period":"ytd","weight":0.118}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.228208},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.167334},{"month":3,"riseRate":0,"avgChangeRate":-0.107746},{"month":4,"riseRate":0.666667,"avgChangeRate":0.104894},{"month":5,"riseRate":0.666667,"avgChangeRate":0.101166},{"month":6,"riseRate":0.666667,"avgChangeRate":0.282829},{"month":7,"riseRate":0.333333,"avgChangeRate":0.014223},{"month":8,"riseRate":0.25,"avgChangeRate":-0.004679},{"month":9,"riseRate":0.25,"avgChangeRate":-0.100061},{"month":10,"riseRate":0.666667,"avgChangeRate":0.172366},{"month":11,"riseRate":0.666667,"avgChangeRate":-0.001337},{"month":12,"riseRate":0.333333,"avgChangeRate":0.009885}],"exchange":"NASDAQ","name":"Sagimet Biosciences Inc.","nameEN":"Sagimet Biosciences Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Sagimet Biosciences Inc.(SGMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Sagimet Biosciences Inc.,SGMT,Sagimet Biosciences Inc.股票,Sagimet Biosciences Inc.股票老虎,Sagimet Biosciences Inc.股票老虎国际,Sagimet Biosciences Inc.行情,Sagimet Biosciences Inc.股票行情,Sagimet Biosciences Inc.股价,Sagimet Biosciences Inc.股市,Sagimet Biosciences Inc.股票价格,Sagimet Biosciences Inc.股票交易,Sagimet Biosciences Inc.股票购买,Sagimet Biosciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Sagimet Biosciences Inc.(SGMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction